SCHEDULE 13G/A: BlackRock Amends Passive Stake in Phathom Pharmaceuticals, Reports 4.6% Ownership

BlackRock, Inc. has filed an amendment to its Schedule 13G, disclosing a passive beneficial ownership of 4.6% in Phathom Pharmaceuticals, Inc. as of March 31, 2025.

Summary

• BlackRock, Inc. filed an Amendment No. 1 to its Schedule 13G regarding its beneficial ownership in Phathom Pharmaceuticals, Inc.
• The filing indicates BlackRock, Inc. beneficially owns an aggregate of 3,226,286 shares of Phathom Pharmaceuticals, Inc. Common Stock.
• This ownership represents 4.6% of the class of securities.
• BlackRock, Inc. holds sole voting power over 3,158,465 shares and sole dispositive power over 3,226,286 shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
• No single person's interest within BlackRock's holdings is more than five percent of the total outstanding common shares of Phathom Pharmaceuticals, Inc.

Sentiment

Score: 5

Explanation: The document is a factual, routine regulatory filing disclosing passive ownership, with no inherent positive or negative sentiment regarding the issuer's performance or outlook.

Risks

• The filing itself does not detail risks for Phathom Pharmaceuticals, Inc., but rather confirms BlackRock's passive investment stance, indicating no intent to influence control.

Future Outlook

This Schedule 13G filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance regarding Phathom Pharmaceuticals, Inc.'s future performance or BlackRock's future investment intentions beyond its passive stance.

Industry Context

This filing is a routine disclosure by a major institutional investor, BlackRock, Inc., regarding its passive stake in a pharmaceutical company. It reflects standard portfolio management and compliance with SEC reporting requirements for significant ownership thresholds, rather than a strategic industry move or a commentary on the pharmaceutical sector's trends.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's passive stake, confirming BlackRock's position as a holder without intent to influence control.
• Management: Informs management of a major institutional shareholder's position, which is held for investment purposes only.

Key Dates

Keywords

BlackRock, Phathom Pharmaceuticals, Schedule 13G, Beneficial Ownership, Common Stock, Passive Investment, SEC Filing, Institutional Investor